Streetbeat News

Analyst Ratings

CRBU

HC Wainwright & Co. has reiterated its Buy rating on Caribou Biosciences, maintaining a price target of $9.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 3:10 pm

COGT

HC Wainwright & Co. has maintained a Buy rating on Cogent Biosciences but lowered the price target from $19 to $17.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 3:06 pm

JBL

Jabil (NYSE:JBL) has seen a shift in analyst sentiment, with a decrease in the average 12-month price target by 7.04%. Analysts have lowered their ratings and price targets, reflecting concerns over Jabil's recent financial performance, including a 20.18% decline in revenue growth. Despite this, Jabil maintains strong net margins and return on equity, though its high debt-to-equity ratio raises concerns.

Portfolio Pulse from Benzinga Insights

September 03, 2024 | 3:01 pm

VALN

Valneva (NASDAQ:VALN) has received six bullish analyst ratings over the past three months, with a consistent price target of $26.00. Despite a negative revenue trend, Valneva shows strong net margin and ROE compared to industry averages. However, it faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

September 03, 2024 | 3:00 pm

CC

Chemours (NYSE:CC) has received mixed analyst ratings over the past three months, with a recent decline in the average 12-month price target from $29.50 to $25.14. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Despite a decline in revenue growth, Chemours maintains strong profitability with a high net margin and effective debt management.

Portfolio Pulse from Benzinga Insights

September 03, 2024 | 3:00 pm

NMRK

Newmark Group (NASDAQ:NMRK) has received mixed analyst ratings over the past three months, with a recent increase in average price target to $14.62. Analysts have raised their ratings and price targets, reflecting positive sentiment. Despite strong financial metrics like net margin and ROE, the company faces challenges with its debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 03, 2024 | 3:00 pm

INCY

Incyte (NASDAQ:INCY) has been analyzed by 9 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $67.11, up 3.07% from the previous target. Analysts have adjusted their ratings and price targets, reflecting their views on Incyte's market performance. Despite a 9.34% revenue growth, Incyte's financial metrics like net margin, ROE, and ROA are below industry averages, indicating challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

September 03, 2024 | 3:00 pm

BLDR

Over the past three months, 14 analysts have evaluated Builders FirstSource (NYSE:BLDR), with a mix of bullish and bearish opinions. The average 12-month price target has decreased by 6.72% to $190.57. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Builders FirstSource faces challenges in revenue growth, net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

September 03, 2024 | 3:00 pm

FTLF

FitLife Brands Inc (NASDAQ:FTLF) is expected to see strong revenue growth and cost savings, driven by M&A activities and a focus on online sales. Analyst Sean McGowan from Roth Capital Partners initiated coverage with a Buy rating and a $40 price target.

Portfolio Pulse from Priya Nigam

September 03, 2024 | 2:57 pm

OPT

HC Wainwright & Co. has maintained a Buy rating on Opthea (NASDAQ:OPT) but lowered the price target from $14 to $12.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 2:56 pm